anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Education mode 3 (dynamic interface) participants will be educated using the digitized traditional materials from education mode 2 as well as an enhanced dynamic e-journal (visualization of blood glucose and alerts). In addition, this mode will provide informative disease-related internet sites and diabetes news and articles vetted by the medical team. Participants and health professionals will then be able to electronically discuss the content and quality of this information (discussion board). New sites and articles will be added on an ongoing basis. Participants will also have access to a chat room that will encourage information sharing with other education mode 3 participants and health professionals at CHR. Education mode 3 will be assessed and approved by CHR.
A computer-implemented method of optically determining an estimated age of a skin (112) of a living being, specifically of a human being, is proposed. The method comprises: i. using at least one sample reflection spectrum of at least one portion of the skin (112) of the living being over a spectral measurement range, the spectral measurement range comprising at least one portion of the wavelength range of 1 µm to 2.5 µm; and ii. determining the estimated age of the skin (112) of the living being by applying, to the sample reflection spectrum, at least one trained trainable model. The trainable model is trained on a training dataset comprising a plurality of labeled reference reflection spectra. Each of the reference reflection spectra is acquired over a spectral range at least partially overlapping with the spectral measurement range of the sample reflection spectrum of step i.. Each of the reference reflection spectra is a reflection spectrum of at least one portion of a skin (112) of a living test being having a known age. The reference reflection spectra are at least partially labeled with at least the known age of the corresponding living test being.
Kyphosis is a posterior convexity of the spine. Children with cerebral palsy show a higher probability of progression of the kyphotic curve. If it is not adequately treated, it becomes fixed where it requires surgical management. Children with cerebral palsy have more probability to balance impairment and falls than normal children and the consequences of that fall are great. The current studies do not properly examine the effectiveness of conservative orthoses on the therapeutic management of kyphosis in children with cerebral palsy. Also, there is a shortage of studies that evaluate how correction of the thoracic kyphosis influences the balance performance and fall risk in children with cerebral palsy. TheraTogs orthosis which consists of an orthotic undergarment and external strapping system has been designed to provide a soft and passive body compression to maintain a typical body postural alignment and to improve posture control. Therefore, the objective of this study was to investigate how the correction of dorsal hyper-kyphotic posture by the TheraTogs orthotic system could influence balance control, and fall risk in cerebral palsied children of spastic diplegia.
PURPOSE:To obtain an excellent antiretroviral agent containing an anthracycline based antibiotic substance as an active ingredient with hardly any toxicity. CONSTITUTION:An antiretroviral agent containing an anthracycline based antibiotic substance, such as daunorubicin or doxorubicin, having antitumor activity as an active ingredient. The above-mentioned agent is useful for treating one kind of retroviral AIDS and adult type T cell leukemia. The dose of the antibiotic substance which is a principal ingredient is normally preferably 4-800mg per day for an adult depending on the activity, toxicity, administration route, etc., of the individual drugs. The daunorubicin and doxorubicin exhibit better antiretroviral action than that of azidothymidine or bleomycin. The afore- mentioned agent is effective not only against patients infected with retroviruses but also against carriers without manifesting symptoms.
Introduction: The ketogenic diet is a therapeutic option for the control of drug-resistant epileptic seizures. It is based on high fat consumption, protein control and carbohydrate restriction. As a result, the body uses fat as an energy substrate instead of glucose. Changing the patient's daily menu and eating routine is hard and requires dedication from the caregiver for the best therapeutic result. In clinical practice, the diet becomes monotonous and poorly accepted by the patient over time. Besides, there is a difficulty in understanding nutritional guidelines. It is necessary to develop strategies to increase adherence to treatment, palatability of meals and diversify the foods offered to patients. Objective: To evaluate the effectiveness of creating a ketogenic kitchen in improving compliance of patients with CD in the outpatient clinic of Instituto da Criança - HCFMUSP. Methods: this work will be carried out in 4 steps: (1st) Creation and validation of a questionnaire of ketogenic diet compliance, (2nd) Creation of ketogenic recipes of easy preparation and low cost, (3rd) Incorporation of culinary workshops and supply of recipes for patients undergoing treatment at Instituto da Criança - HCFMUSP and (4th) Application of the questionnaire of ketogenic diet compliance.
OBJECTIVE: Many studies have found that miR-26a-5p plays an essential role in the progression of pathological cardiac hypertrophy, however, there is still no evidence on whether miR-26a-5p is related to the activation of autophagy and NLRP3 inflammasome. And the mechanism of miR-26a-5p and NLRP3 inflammasome aggravating pathological cardiac hypertrophy remain unclear.
METHODS: Cardiomyocytes were treated with 200µM PE to induce cardiac hypertrophy and intervened with 10mM NLRP3 inhibitor INF39. In addition, we also used the MiR-26a-5p mimic and inhibitor to transfect PE-induced cardiac hypertrophy. RT-qPCR and western blotting were used to detect the expressions of miR-26a-5p, NLRP3, ASC and Caspase-1 in each group, and we used α-SMA immunofluorescence to detect the change of cardiomyocyte area. The expression levels of autophagy proteins LC3, beclin-1 and p62 were detected by western blotting. Finally, we induced the SD rat cardiac hypertrophy model through aortic constriction (TAC) surgery. In the experimental group, rats were intervened with MiR-26a-5p mimic, MiR-26a-5p inhibitor, autophagy inhibitor 3-MA, and autophagy activator Rapamycin.
RESULTS: In cell experiments, we observed that the expression of miR-26a-5p was associated with cardiomyocyte hypertrophy and increased surface area. Furthermore, miR-26a-5p facilitated autophagy and activated the NLRP3 inflammasome pathway, which caused changes in the expression of genes and proteins including LC3, beclin-1, p62, ACS, NLRP3, and Caspase-1. We discovered similar outcomes in the TAC rat model, where miR-26a-5p expression corresponded with cardiomyocyte enlargement and fibrosis in the cardiac interstitial and perivascular regions. In conclusion, miR-26a-5p has the potential to regulate autophagy and activate the NLRP3 inflammasome, contributing to the development of cardiomyocyte hypertrophy.
CONCLUSION: Our study found a relationship between the expression of miR-26a-5p and cardiomyocyte hypertrophy. The mechanism behind this relationship appears to involve the activation of the NLRP3 inflammasome pathway, which is caused by miR-26a-5p promoting autophagy. Targeting the expression of miR-26a-5p, as well as inhibiting the activation of autophagy and the NLRP3 inflammasome pathway, could offer additional treatments for pathological cardiac hypertrophy.
A medical device known as an implantable therapeutic substance infusion device is configured for implanting in humans to deliver a therapeutic substance such as pharmaceutical compositions, genetic materials, and biologics to treat a variety of medical conditions such as pain, spastisity, cancer, and many other conditions. The therapeutic substance infusion device has a piston pump with an anti-cavitation valve to reduce gas formation, increase accuracy, improve efficiency and has many other improvements. The therapeutic substance infusion device has a housing, a therapeutic substance reservoir, a power source carried in the housing, electronics, a piston pump, an inlet valve, and anti-cavitation valve. The piston pump is configured for pumping therapeutic substance from the therapeutic substance reservoir through an infusion port at a programmed rate. The anti-cavitation is in fluid communication with a reservoir outlet and an inlet chamber to substantially preventing retrograde flow of therapeutic substance from the inlet chamber back through the reservoir outlet. Many embodiments of the anti-cavitation valve and its methods of operation are possible.
Canine tumours including urothelial carcinoma, lung adenocarcinoma, mammary gland tumour, squamous cell carcinoma, and melanoma have been identified as causes of death, but effective therapies are limited due to insufficient knowledge of the molecular mechanisms involved. Within the tumour microenvironment, hypoxia activates hypoxia-inducible factor 1α (HIF1α) in tumour cells. High HIF1α expression correlates with enhanced glycolysis and poorer outcomes in human cancers. However, the molecular mechanisms underlying hypoxic tumour cells remain elusive in dogs. In our study, we investigated upregulated genes in a canine malignant melanoma cell line during hypoxia using RNA-sequencing analysis. Glycolysis and HIF1 signalling pathways were upregulated in hypoxic melanoma cells. HIF1α knockout melanoma cells revealed that the glycolysis marker MCT4 is regulated by HIF1α activation. Hypoxia induces high lactate secretion due to enhanced glycolysis in canine melanoma cells. Furthermore, we examined monocarboxylate transporter 4 (MCT4) expression in malignant melanoma and eight other types of canine tumour tissues using immunohistochemistry (IHC). Membrane-localized MCT4 protein was mostly detected in urothelial carcinoma and lung adenocarcinoma rather than malignant melanoma. We conclude that canine MCT4 protein plays a role in lactic acid efflux from glycolytic cells and may serve as a marker for hypoxia and glycolysis in canine tumours. These findings could inform future therapeutic strategies targeting MCT4.
The primary aim of this study was to compare the effect of prewarming on perioperative hypothermia in elderly patients undergoing TURP under general anesthesia. In addition, we aimed to evaluate the effects of prewarming on hemodynamic variables, PACU output time, tremor, patient comfort and satisfaction. The investigators plan to enroll 36 patients in 2 groups. Body temperature will be measured at the core temperature, hemodynamic variables. Shivering will be graded by visual inspection. Thermal discomfort scale, patient satisfaction will be evaluated. The investigators hypothesize will decrease the forced air prewarming incidence of perioperative hypothermia.
The investigational new drug (FolateScan or Technetium Tc 99m EC20) is a folate-targeted diagnostic radiopharmaceutical designed to bind to the folate receptor. The folate receptor is a glycoprotein that is over-expressed in many types of cancer cells but it is only minimally distributed in normal tissues. Folate conjugates bind to the folate receptor with high affinity and are brought into the cell via endocytosis. In contrast, folic acid itself enters most normal cells via the reduced folate carrier, a pathway entirely inaccessible to folate conjugates. Therefore, these folate conjugates are specific to cancer cells.

Endocyte's folate-targeted delivery system was applied towards the targeting of a diagnostic imaging agent (111In-DTPA-Folate) to ovarian cancer tumors. This proof-of-principle study was designed to demonstrate the ability of folate to target drugs to folate-receptor-positive (FR+) cancer tissue.
This arm will receive services as usual plus the Work Chat intervention over a series of a few weeks. We estimate approximately 15-18 hours of training will occur.
Previous studies suggest that trait disinhibition as measured by the Three Factor eating Questionnaire (TFEQ) is related to selected measures of impulsivity and risk taking. However, the factor validity of the original trait disinhibition measure has been questioned, and a revised scale of uncontrolled eating consequently developed. To date few studies have revisited the relationship between impulsivity and the uncontrolled and emotional eating scales of the revised TFEQ. In the present study, 283 participants (208 women) completed the revised TFEQ alongside a battery of measures of impulsivity and risk taking in an online study. The total and all subscale scores on the Barratt Impulsiveness Scale were significantly associated with scores on the uncontrolled, but not emotional or restrained, TFEQ scale. Likewise, risky behaviour indexed by the average number of pumps per trial on the Balloon Analogue Risk Task were also associated with uncontrolled, but not emotional or restrained, eating, and the same pattern of associations were also found for the novelty, but not intensity, subscales of the Arnetts Inventory of Sensation Seeking. Overall these data suggest that uncontrolled eating is related to wider personality traits of risky decision making, novelty seeking and wider cognitive impulsivity, which may in turn increase of future weight gain.
Hematopoietic stem cell transplantation (HSCT) has been commonly used as a potentially curative option in the treatment of various hematological malignancies. However, it may end up with serious complications in various systems, including the hemostatic system. HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure, mental status changes and involvement of other organs. Since the pathophysiology has not been clarified, there are no established treatments for TA-TMA several agents seem to have successful results. N-Acetylcysteine (NAC) is a small, simple molecule that began as a generic drug almost 40 years ago. It has since been approved by the FDA for many indications. Studies showed NAC reduce plasma VWF multimers and VWF multimeric size without an effect on the bleeding time in vitro and in vivo, thus proposed as a possible supplementary treatment for TTP. The investigators conducted an prospective clinical trial to evaluate the safety and efficiency of NAC in patients with TA-TMA.
The present invention comprises a central processing unit, multiple controlled medicine box units, and mobile management unit. The central processing unit comprises multiple controlled medicine data and a timer. Each controlled medicine box unit contains one controlled medicine and includes an electronic display unit. The electronic display unit is in wireless connection with the central processing unit to display the controlled medicine data. The mobile management unit is in wireless connection with the central processing unit. When the timer is in a compulsory inventory mode, the controlled medicine data display a medicine code, a medicine name, and medical data, but not a quantity of the medicine. After the inventory is completed, and the quantity of the medicine is entered through the mobile management unit and is checked by the central processing unit as being matched, the quantity of the medicine is displayed. If it is not matched, an alert message is displayed. The present invention features advantages of compulsory inventory during a shift change, electronic displaying of medicine quantity to allow a pharmacist to handle medicine condition easily, and ease of modifying data of controlled medicines.
The results of the early OGTT conducted before 16 weeks' gestation will be revealed to the participants. If the results indicate gestational diabetes mellitus (GDM) by the WHO 2013 criteria, immediate follow-up actions, including appropriate treatments, will be taken. Those with a normal result will undertake the universally offered routine OGTT at 24-28 weeks' gestation.
Disclosed is a method of manufacturing a spherical seamless capsule formed by encapsulating a filler material such as a medicine with a capsule shell material such as gelatin. A concentric multiple nozzle is positioned above the liquid surface of a curing liquid such that the tip of the nozzle faces down. A concentric columnar composite flow which is discharged from this concentric multiple nozzle and which is composed of a filler material and a capsule shell material outside the filler material is immersed in the curing liquid, and cut in the curing liquid to form a droplet. The capsule shell material of the droplet is cured by the curing liquid, and thereby a seamless capsule is formed. Since, the droplet is not dropped into the curing liquid, no deformation of the droplet caused by collision against the liquid surface occurs. The tip of the multiple nozzle is positioned above the liquid surface of the curing liquid. This prevents water contained in the curing liquid from adhering to the surface of the nozzle and penetrating into the composite flow.
The invention relates to the field of biotechnology, medicine, and veterinary and can be used for anthrax prevention and treatment. The proposed drug has a bactericidal effect on vegetative and spore cells of  Bacillus anthracis  and comprises a bacteriolytic complex produced by bacterial strain  Lysobacter  sp. XL 1. The bacteriolytic complex produced by the above bacterial strain is used as acting substance in the method of anthrax prevention and treatment. Prevention is realized through subcutaneous injection of the preparation with single introduction of bacteriolytic complex solution no later than in 3 h after the infection, or application of a bandage (tissue paper) sodden with the active substance to supposed place of pathogen penetration, or treatment of the probable nidus of infection with aerosol. The skin form of anthrax is treated by subcutaneous injections, encompassing injections around or aerosol treatment of lesion focus; subcutaneous injections of the proposed preparation are used for generalized forms. The bacteriolytic complex is used as solution in phosphate buffer; the solution is prepared immediately before application.
This is a phase II, single institution trial to correlate gefitinib response and mutations in the protein-tyrosine kinase domain of the EGF receptor gene. The study will be conducted in patients with Stage I and II NSCLC who have been determined to be operable and resectable.

Patients must have 1 or more of the following features: never smoker or smoking history of \< 15 pack years and/or features of bronchioloalveolar lung cancer. 50 patients will be enrolled on this study. Treatment will be with gefitinib for at least 21 days before surgery (depending on the timing of the surgery). Patients will discontinue gefitinib 2 days before their operation. For patients that demonstrate a radiographic response to gefitinib preoperatively and /or patients with mutations in the protein-tyrosine kinase domain of the EGF receptor gene (identified from the surgical sample), gefitinib will continue for 2 years post-surgery. Patients who do not have evidence of radiographic response or mutations in the protein-tyrosine kinase domain of the EGF receptor gene will be removed from the study.
BACKGROUND: Knee pain is a prominent concern among older individuals, influenced by the central nervous system. This study aimed to translate the Central Aspects of Pain in the Knee (CAP-Knee) questionnaire into Japanese and investigate its reliability and validity in older Japanese individuals with knee pain.
METHODS: Using a forward-backward method, CAP-Knee was translated into Japanese, and data from 110 patients at an orthopedic clinic were analyzed. The Japanese version (CAP-Knee-J) was evaluated regarding pain intensity during walking, central sensitization inventory, and pain catastrophizing scale. Statistical analyses confirmed internal validity and test-retest reliability. Concurrent validity was assessed through a single correlation analysis between CAP-Knee-J and the aforementioned measures. Exploratory factor analysis was employed on each CAP-Knee-J item to examine structural validity.
RESULTS: CAP-Knee-J showed good internal consistency (Cronbach's α = 0.86) and excellent test-retest reliability (intraclass correlation coefficient = 0.77). It correlated significantly with pain intensity while walking, central sensitization inventory scores, and pain catastrophizing scale scores. Exploratory factor analysis produced a three-factor model.
CONCLUSIONS: CAP-Knee-J is a reliable and valid questionnaire for assessing central pain mechanisms specific to knee pain in older Japanese individuals, with moderate correlations with the CSI and weak with the PCS, thus indicating construct validity. This study supports the development of effective knee pain treatments and prognosis predictions.
The invention provides a light curing method, including: providing a light curing apparatus having at least one light source, at least one fan and a curing volume. A first polymerizable shaped material is positioned within the curing volume. The light source and the fan are controlled to heat the first polymerizable shaped material to temperatures within a first temperature range. The light source and the fan are controlled to maintain the first polymerizable shaped material at temperatures within the first temperature range for at least 1 minute. A second polymerizable shaped material is positioned within the curing volume. The light source and the fan are controlled to heat the second polymerizuable shaped material to temperatures eithin a second temperature range. The light source and the fan are controlled to maintain the second polymerizable shaped material at temperatures within the second temperature range for at least 1 minute. The first temperature range has afirst midpoint and the second temperature range has a second midpoint. The first midpoint is at least 15 ~C from the second midpoint.
A complementary DNA (cDNA) encoding full length form of ICE rel  -III is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE rel  -III. The cDNA and the recombinant ICE rel  -III protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE rel  -III protein may be used to identify compounds that affect ICE rel  -III function, inflammation and cell apoptosis. ICE rel  -III function, inflammation and cell apoptosis may also be modulated by ICE rel  -III antisense or gene therapy.
The present disclosure discloses an antibody combination for substituting a side scatter signal in mass cytometry hematologic tumor immunophenotyping, including a Lactoferrin antibody and a Lysozyme antibody. The present disclosure also discloses a gating method for mass cytometry hematologic tumor immunophenotyping. The present disclosure also discloses a kit for mass cytometry hematologic tumor immunophenotyping. According to the present disclosure, the Lactoferrin antibody and the Lysozyme antibody are used for the first time, are combined with a CD45 antibody for two-stage gating strategy, and are combined with a mass cytometer to substitute traditional flow cytometry CD45/SSC to distinguish mature granulocytes, monocytes, nucleated red blood cells, lymphocytes, primitive and juvenile cells, and abnormal cell subsets in bone marrow. This overcomes the technical difficulty that the mass cytometry cannot detect SSC in hematologic tumor cell analysis. Combined with the multi-parameter high-throughput characteristics of the mass cytometry, the present disclosure can improve the depth of the current hematologic tumor immunophenotyping.